7T MRS in Parkinson's Disease

NCT ID: NCT01237210

Last Updated: 2019-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

78 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-02-28

Study Completion Date

2019-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is looking for healthy controls and patients with Parkinson's (PD) to perform an MR scan.

1. The neurochemical profile of the SN of patients with PD as measured by high field MRS will differ from that of healthy controls, in that glutathione will be lower due to oxidative stress, lactate will be higher due to mitochondrial dysfunction, the gliosis markers myo-inositol and glutamine will be higher due to inflammation (glial activation) and N-acetylaspartate and glutamate will be lower due to neuronal loss/damage.
2. There will be a relationship between neurochemical changes and disease severity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Parkinson's disease Group

* Parkinson's disease (clinical diagnostic criteria)
* Age 45-75 years inclusive
* Able to safely undergo MRI scanning
* Absence of diabetes and smoking
* Capable of giving informed consent

Healthy Control Group

* Age 45-75 years inclusive
* Able to safely undergo MRI scanning
* Absence of diabetes and smoking
* Capable of giving informed consent

Exclusion Criteria

Parkinson's disease Group

* Dementia (clinically determined by PI Dr. Tuite)
* Diagnosis of atypical parkinsonism
* Inability to safely undergo MRI scanning
* Inability to give informed consent
* Unstable medical conditions
* Present smoker
* Diabetic (on oral or injectable medications for diabetes)
* Taken coenzyme Q10 or Vitamin E in the 2 weeks prior to the scan
* Does not meet age criteria

Healthy Control Group

* Has a 1st degree relative with PD
* Dementia (clinically determined by PI Dr. Tuite)
* Inability to safely undergo MRI scanning
* Inability to give informed consent
* Unstable medical conditions
* Present smoker
* Diabetic (on oral or injectable medications for diabetes)
* Taken coenzyme Q10 or Vitamin E in the 2 weeks prior to the scan
* Does not meet age criteria
Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Minnesota

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul Tuite, MD

Role: PRINCIPAL_INVESTIGATOR

University of Minnesota

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Minnesota/CMRR

Minneapolis, Minnesota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0803M28421

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.